PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15499133

Neonatal coagulation problems.

E A Chalmers
View original source ↗Export metadata ↓

Abstract

Bleeding problems often occur during the neonatal period. Although thrombocytopenia is the most common cause, coagulation problems often occur, and the two problems may co-exist. The causes, diagnosis, and management of coagulation problems in newborn infants are reviewed.

Explore related subjects

Blood Coagulation DisordersCoagulation Protein DisordersHemophilia AHemostasisHumansInfant, NewbornVitamin K Deficiencyvon Willebrand DiseasesJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E A Chalmers. 2004. Neonatal coagulation problems.. https://doi.org/10.1136/adc.2004.050096

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Prolonged severe pancytopenia preceding the cutaneous lesions of juvenile xanthogranuloma.

We report a case of juvenile xanthogranuloma (JXG) having progressive pancytopenia for 6 months until the proliferating skin lesions. A 2-month-old infant presented recurrent fever, anemia, and hepatosplenomegaly mimicking hemophagocytic lymphohistiocytosis (HLH) or juvenile myelomonocytic leukemia (JMML). At 8 months of age, the biopsy of a growing papule on the elbow made the diagnosis. Bone marrow (BM) specimens showed clustering foamy cells including hemophagocytosis by histiocytes. Treatment with etoposide followed by vinblastine plus prednisolone (PSL) therapy improved the disease. Although JXG is a benign non-Langerhans cell histiocytosis, the multisystem-visceral form should be considered as a potential aggressive disease when associated with BM failure in early infancy.

Blood Coagulation Disorders↗
PubMed2006

Treating coagulopathy in liver disease with plasma transfusions or recombinant factor VIIa: an evidence-based review.

In severe liver disease, poor synthetic function leads to characteristic deficiencies in numerous coagulation factors, and plasma transfusions are frequently administered to treat or prevent bleeding. This chapter reviews the available English-language randomized controlled trials, evidence-based practice guidelines, and observational studies relevant to establishing criteria for plasma transfusions in liver disease. The alternatives of pathogen-inactivated plasmas and recombinant factor VIIa were also reviewed from this perspective. In current guidelines, plasma transfusions are justified when haemostasis is needed for bleeding or invasive procedures, and the prothrombin time (PT) or partial thromboplastin time (PTT) is >1.5 times normal (mid-normal or, for PTT, sometimes upper limit). Conversion of the PT to the International Normalized Ratio has not been validated in liver disease. Solvent-detergent or methylene-blue treatments alter various clotting factors, which might affect efficacy in liver disease. Recombinant factor VIIa improves laboratory clotting measurements, but reduction of bleeding is less well established to date.

Blood Coagulation Disorders↗